Notable Quotes
| "We believe that VIVE is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017." | ❭ |
More Experts
| "On the back of DRRX's solid deal with Sandoz and with more catalysts to come in 2017 such as Posimir Phase 3 readout in 4Q17 and IND filings for DUR-928, we see potential near-term upside." | ❭ |
–
Charles Duncan, Piper Jaffray & Co.
| "We believe VIVE's Phase 3 trial is on track for a readout of data in mid-2019." | ❭ |
